← All trials
NCT05219435
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2022
- Primary completion
- Mar 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Feb 2, 2022
- Last posted
- Dec 5, 2022
- Enrollment
- 66
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spanish Oncology Genito-Urinary GroupLead sponsor
- Universidad Complutense de MadridStudy chair
- Bristol-Myers SquibbCollaborator
- Universidad Complutense de MadridOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.